GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 120 | 92 | 0 | 89 | 1 |
| Inventories | 12 | 12 | N/A | N/A | N/A |
| TOTAL | $144 | $104 | $343 | $194 | $96 |
| Non-Current Assets | |||||
| Intangibles | 22 | 25 | 28 | 34 | 41 |
| TOTAL | $22 | $25 | $28 | $34 | $41 |
| Total Assets | $166 | $129 | $371 | $228 | $137 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,937 | 1,770 | 1,644 | 1,867 | 1,823 |
| Accounts payable and accrued liabilities | 815 | 806 | 974 | 772 | 856 |
| Accrued Expenses | 2,111 | 2,205 | 2,171 | 1,952 | 3,283 |
| Other current liabilities | 303 | 158 | 290 | 980 | 984 |
| TOTAL | $5,429 | $5,230 | $5,277 | $5,798 | $7,161 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,429 | $5,230 | $5,277 | $5,798 | $7,161 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 329,799 | 300,300 | 238,623 | 215,423 | 191,245 |
| Common Shares | 300 | 269 | 239 | 209 | 170 |
| Retained earnings | -84,410 | -83,795 | -82,657 | -82,680 | -82,018 |
| Other shareholders' equity | 3 | 3 | 3 | 3 | 3 |
| TOTAL | $-5,263 | $-5,101 | $-4,906 | $-5,570 | $-7,024 |
| Total Liabilities And Equity | $166 | $129 | $371 | $228 | $137 |